What kinds of studies have been published on RU-58841?

The four papers opened for this page are a 1994 hamster and rat study (Battmann et al.), a 1994 rat pharmacokinetics study (Cousty-Berlin et al.), a 1997 human scalp graft on nude mice study (De Brouwer et al.) and a 1998 PC3 cell and stump-tailed macaque study (Pan et al.). None is a human clinical trial.

Do those studies show RU-58841 is safe for people?

No. They were done in animals and cell lines and do not establish safety or effect in people. Norwood Labs sells RU-58841 only as an unlicensed research compound for laboratory use.

What did the 1994 rat pharmacokinetics study report?

Cousty-Berlin et al. (1994) reported an elimination half-life of the order of 1 hour after a 10 mg/kg intravenous dose in rats. This describes rats given an injection, not any other species or route.

RU-58841 Published Studies: Animal and Cell Work (1994-1998)

Key facts (as of October 2026)

The published RU-58841 papers opened for this page are animal and cell-line studies from 1994 to 1998.
None of them is a human clinical trial.
Each study used one narrow model, so none can be read as a statement about people.
Abstracts were read on PubMed on 25 October 2026.

The short version

Four papers: hamster and rat, rat pharmacokinetics, human scalp grafts on mice, and cell line plus macaque.
They describe results in those models. They do not establish safety or effect in people.
Read the abstract and limits for each before citing any of them.

Battmann et al., 1994

Journal of Steroid Biochemistry and Molecular Biology, PMID 8136306. Model: hamster flank organ and rat. The abstract reports that topical application reduced flank organ area at 1 microgram per animal, with weak systemic activity after subcutaneous 300 micrograms and no effects in intact rats up to 1 microgram. Limit: animal model only.

Cousty-Berlin et al., 1994

PMID 7947350. Model: rat plasma. The abstract reports a half-life of the order of 1 hour after a 10 mg/kg intravenous dose, and describes conversion to a metabolite that is itself antiandrogenic. Limit: rat, intravenous dosing only. For more on this paper see RU58841 half-life and systemic absorption.

De Brouwer et al., 1997

British Journal of Dermatology, PMID 9415227. Model: balding human scalp grafts on nude mice. The abstract reports 20 grafts, with 29 active follicles against 28 in controls, a second cycle in 8 (28%) against 2 (7%), and a higher linear hair growth rate (P<0.04). Limit: a small mouse xenograft study using 1% in ethanol.

Pan et al., 1998

Endocrine, August 1998, PMID 9798729. Models: PC3 cells and the stump-tailed macaque. The abstract reports competitive suppression of DHT activation of the androgen receptor, hair changes in the macaque model and no systemic effects detected. Limit: cell line and macaque only.

Evidence gap

No human clinical trial of RU-58841 was found in the sources opened for this page. For how the compound compares with pyrilutamide, which does have company-reported human trials, see RU-58841 vs pyrilutamide.

Research use only

RU-58841 is not an approved medicine anywhere. Norwood Labs sells it as an unlicensed research compound, strictly for laboratory research use. It is not for human consumption.

Shop

RU-58841 5% Solution

Published sample report.

View product →

Shop

RU-58841 Powder

2 g, 5 g and 10 g · published sample reports.

View product →